Final MolDX LCDs Unlock Tailored Molecular Monitoring Through Pre-Transplant Risk Stratification

The finalized MolDX and Noridian Local Coverage Determinations (LCDs) for Molecular Testing for Solid Organ Allograft Rejection(DL40058, DL40060, and L38568) represent an important milestone for transplant medicine. By securing long-term Medicare reimbursement for non-invasive surveillance methods such as donor-derived cell-free DNA (dd-cfDNA) testing, these guidelines provide greater certainty for transplant centers while expanding access to molecular monitoring.

Pirche strongly supports these finalized coverage decisions and believes they reinforce the value of combining pre-transplant molecular risk stratification with post-transplant monitoring to enable more personalized patient care.

Clinical Certainty and Pre-Transplant Synergy

By guaranteeing coverage for critical post-operative phases, including up to six tests in the first year alongside reliable long-term follow-ups, the new guidelines provide transplant centers with vital planning stability. This expanded access enables early intervention before irreversible organ damage occurs and significantly reduces the need for invasive protocol biopsies.

While post-transplant molecular tests reflect active organ stress, PIRCHE delivers the essential baseline before surgery. Through advanced digital molecular matching, PIRCHE accurately predicts a patient’s immunological risk profile.

"The full medical and economic value of these new MolDX guidelines is unlocked when we understand a patient's pre-transplant risk," states Pirche’s CEO Thomas Klein. "With PIRCHE, clinics can customize monitoring schedules, ensuring high-risk patients receive intensive, tailored surveillance from day one."

A Win-Win for Clinics and Test Providers

This integrated diagnostic approach optimizes the entire transplantation ecosystem:

• For Clinicians: It provides greater confidence when personalizing immunosuppression and follow-up care by identifying high-risk patients immediately.
• FoFor Test Providers: PIRCHE’s pre-transplant risk assessment delivers the clinical evidence needed to justify and implement extended, reimbursed monitoring protocols for high-risk patients under the new LCDs

By bridging pre-transplant risk with post-transplantmonitoring, Pirche stands as the ideal partner for transplant centers and diagnostic providers looking to implement these new reimbursement guidelines effectively.

‍